Financial Performance - The company's operating revenue for the first half of 2024 was CNY 4,252,338,864.23, representing a 9.02% increase compared to CNY 3,900,625,795.05 in the same period last year[10]. - The net profit attributable to shareholders for the first half of 2024 was CNY 1,240,798,423.17, a slight increase of 0.15% from CNY 1,238,999,444.63 in the previous year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 6.03%, amounting to CNY 1,128,729,566.55 compared to CNY 1,201,167,722.56 in the same period last year[10]. - The basic earnings per share for the first half of 2024 was CNY 0.187, reflecting a 1.63% increase from CNY 0.184 in the same period last year[10]. - The total assets at the end of the reporting period were CNY 32,372,700,012.22, which is a 1.39% increase from CNY 31,928,453,993.18 at the end of the previous year[10]. - The net assets attributable to shareholders increased by 3.75%, reaching CNY 30,746,632,018.70 compared to CNY 29,633,949,195.13 at the end of the previous year[10]. - The weighted average return on net assets was 4.10%, a decrease of 0.07 percentage points from 4.17% in the previous year[10]. - The total operating revenue for the first half of 2024 reached CNY 4,252,338,864.23, an increase of 9.0% compared to CNY 3,900,625,795.05 in the same period of 2023[177]. - Total operating costs amounted to CNY 3,044,769,048.29, up 13.1% from CNY 2,691,638,281.71 year-on-year[177]. - Operating profit for the first half of 2024 was CNY 1,548,819,448.69, reflecting a slight increase from CNY 1,458,463,554.09 in the previous year[177]. Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -47,549,432.62, a significant decline of 103.32% from CNY 1,433,444,222.02 in the previous year[10]. - The company reported a cash and cash equivalents balance of 1,891,837,596.46 RMB at the end of the first half of 2024, down from 3,542,092,429.90 RMB a year earlier[183]. - Cash inflow from operating activities totaled 1,176,910,017.45 RMB, slightly up from 1,078,045,270.62 RMB in the previous year[184]. - Total cash outflow from operating activities was 772,524,350.45 RMB, compared to 674,774,901.94 RMB in the same period of 2023[184]. - The company reported a significant increase in export revenue, which rose by 351.55% to ¥30,127,465.80, indicating successful international market expansion[32]. - The company reported a total of CNY 348,617.97 in other income, which adds to the overall revenue stream[195]. Research and Development - Research and development expenses rose by 22.05% to ¥106,025,740.46, reflecting the company's increased investment in R&D projects[31]. - The company is committed to ongoing research and development in blood product technologies to enhance its product offerings[14]. - The company has allocated 100 million RMB for R&D in new technologies related to blood product safety and efficacy[71]. - The company successfully obtained clinical approval for its first global monoclonal antibody treatment for hemophilia, SR604 injection, which is currently in the patient enrollment phase[26]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[177]. Market Expansion and Strategy - The company plans to expand its market presence through exclusive distribution agreements for blood products in mainland China[14]. - The company is focusing on building a compliant, professional, and precise marketing system to enhance operational efficiency and ensure regulatory compliance[27]. - The company aims to leverage big data and AI technologies for precise marketing and customer service improvements[27]. - The company is actively pursuing technological upgrades, including a project to enhance the GMP standards for blood products, which is projected to increase production capacity by 100,000 bottles annually[81]. - The company is exploring potential acquisitions of smaller biotech firms to enhance its product portfolio and market reach[70]. Shareholder and Governance - The company announced a cash dividend of CNY 0.37 per 10 shares (including tax) to all shareholders[2]. - The company declared a cash dividend of 0.37 CNY per share, totaling 245,531,438.97 CNY, which represents 100% of the distributable profit[60]. - The total number of shares for the cash dividend distribution is based on 6,635,984,837 shares, excluding shares held in the company's repurchase account[60]. - The company has implemented an employee stock ownership plan, with 30,990,000 shares allocated to 262 participants, representing 0.47% of the total shares[61]. - The company completed the election of the sixth board of directors on July 29, 2024, with a total of 9 directors, of which Haier Group controls the majority[151]. Risks and Challenges - The company faces potential risks including raw material supply risks and rising plasma costs, which may impact future operations[2]. - The company faces risks related to the supply of raw plasma, which remains tight due to regulatory constraints, impacting production capacity[55]. - The company reported a significant increase in costs due to rising wages and inflation, which poses a risk to plasma collection operations[56]. - The company is exposed to foreign exchange risks due to its import trade primarily settled in USD, and it is taking steps to monitor and manage these risks[56]. Environmental Compliance - The company has established a comprehensive waste management strategy, including the use of third-party disposal services for medical and hazardous waste[86]. - The wastewater treatment station has a capacity of 250m³/d, achieving an average COD discharge concentration reduction of over 98.1%[87]. - The company has implemented noise reduction measures, including sound insulation for boiler rooms and generator rooms[91]. - The company has established an emergency response plan for environmental incidents, with the latest revision filed in September 2023[93]. - The company has not reported any exceedance of pollutant discharge limits across various categories, including sulfur dioxide and volatile organic compounds[85]. Acquisitions and Partnerships - GDS acquired the rights and obligations related to the Single Molecule Counting (SMC) technology for $202 million, which is approximately RMB 1.43 billion[11]. - The company has established a strategic partnership with Klibor, which will enhance its market competitiveness and profitability through exclusive distribution agreements for human albumin products in China[28]. - The company is involved in a strategic cooperation agreement with Grifols, focusing on production quality, technology research, and sales channels[142]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and expand its service offerings[200]. Corporate Structure and Changes - The company underwent a change in controlling shareholder to Haiyingkang (Qingdao) Medical Technology Co., Ltd. on July 30, 2024, with Haier Group becoming the actual controller[129]. - The company has not experienced any changes in its board of directors or senior management during the reporting period[59]. - The report indicates that the company is focusing on expanding its market presence and enhancing its product offerings through strategic partnerships[161].

深圳证券交易所文件 深证上〔2024〕609 号 关于对 RAAS China Limited 给予通报批评处分的决定 当事人： 根据上海莱士血液制品股份有限公司（以下简称上海莱士） 于 2023 年 6 月 6 日、2024 年 4 月 30 日披露的《关于 RAAS China Limited 减持公司股份超过 1%暨权益变动的提示性公告》《2024 年一季度报告》，2021 年 3 月 1 日至 2024 年 3 月 31 日，莱士公 司作为上海莱士原持股 5%以上股东，莱士公司及其一致行动人拥 有权益的上海莱士股份比例由 10.42%下降至 3.55%。莱士公司于 2023 年 6 月 1 日首次变动比例达到 5%后，未按照《上市公司收购 管理办法》的规定及时履行报告、公告义务，此后继续通过司法 处置、集中竞价等方式减持上海莱士股份，至 2024 年 3 月 31 日 期间累计变动比例为 6.87%。 莱士公司的上述行为违反了本所《股票上市规则（2023 年 8 月修订）》第 1.4 条、第 2.1.1 条第一款、第 2.1.3 条第一款、第 3.4.1 条第一款、第 3.4.2 条第一款的规定。 鉴 ...

Financial Performance - The company's revenue for Q1 2024 was approximately ¥2.06 billion, a decrease of 0.33% compared to the same period last year[4]. - Net profit attributable to shareholders increased by 5.32% year-on-year, reaching approximately ¥756.82 million[4]. - The net profit after deducting non-recurring gains and losses decreased by 16.64% to approximately ¥590.50 million[4]. - Total operating revenue for the current period is ¥2,056,305,681.88, a slight decrease of 0.35% from ¥2,063,038,679.08 in the previous period[20]. - Net profit for the current period is ¥757,077,509.35, representing an increase of 5.39% compared to ¥718,266,042.76 in the previous period[22]. - Earnings per share (EPS) for the current period is ¥0.114, up from ¥0.107 in the previous period[22]. Cash Flow - The net cash flow from operating activities was approximately ¥750.87 million, down 29.86% from the previous year[4]. - The company reported a decrease in cash flow from operating activities due to reduced receipts and increased payments[9]. - Operating cash flow net amount was $750.87 million, a decrease of 30% compared to $1.07 billion in the previous period[24]. - Cash inflow from operating activities totaled $2.29 billion, slightly down from $2.36 billion year-over-year[24]. - Cash outflow from operating activities increased to $1.54 billion, compared to $1.29 billion in the previous period[24]. - The ending balance of cash and cash equivalents was $4.11 billion, up from $3.63 billion year-over-year[25]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥32.78 billion, an increase of 2.66% from the end of the previous year[4]. - Total assets increased to ¥32,776,666,095.10, compared to ¥31,928,453,993.18 in the previous period, reflecting a growth of 2.66%[19]. - Total liabilities rose to ¥2,316,204,427.85, an increase of 1.00% from ¥2,278,642,620.25 in the previous period[19]. - The total current assets increased to CNY 9.26 billion from CNY 8.68 billion, representing a growth of approximately 6.7%[16]. Investment and Income - Investment income surged by 129.31% to approximately ¥268.70 million, primarily due to gains from the disposal of financial assets[9]. - The company reported investment income of ¥268,696,550.07, significantly higher than ¥117,176,815.83 in the previous period[20]. - The company received $55.70 million in investment income, significantly higher than $23.36 million in the previous period[24]. - Other income increased significantly by 1345.89% to approximately ¥35.10 million, mainly from government subsidies[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 96,910[11]. - Grifols, S.A. holds 26.58% of shares, amounting to 1,766,165,808 shares, making it the largest shareholder[11]. - The company reported a total of 1,766,165,808 unrestricted shares held by Grifols, S.A.[12]. - The total number of shares pledged by RAAS China Limited is 235,908,280[11]. Other Financial Metrics - The weighted average return on equity increased by 0.05 percentage points to 2.52%[4]. - Research and development expenses increased to ¥50,086,978.94, up from ¥46,017,682.81 in the previous period, reflecting a growth of 15.00%[20]. - Other comprehensive income after tax for the current period is ¥47,946,690.97, compared to a loss of ¥190,194,831.87 in the previous period[22]. - Unallocated profits increased to ¥9,075,737,765.69, up from ¥8,318,921,646.19 in the previous period, indicating a growth of 9.12%[19].

Financial Performance - The company's operating revenue for 2023 reached ¥7,963,958,567.30, representing a 21.27% increase compared to ¥6,567,198,581.04 in 2022[11]. - The net profit attributable to shareholders for 2023 was ¥1,779,476,930.19, a decrease of 5.35% from ¥1,880,090,066.90 in 2022[11]. - The net cash flow from operating activities increased by 32.01% to ¥2,277,884,082.33 from ¥1,725,596,063.70 in 2022[11]. - The total assets at the end of 2023 were ¥31,928,453,993.18, up 4.83% from ¥30,457,959,495.12 at the end of 2022[11]. - The net assets attributable to shareholders increased by 2.83% to ¥29,633,949,195.13 from ¥28,818,712,462.60 at the end of 2022[11]. - The company achieved operating revenue of RMB 7.964 billion, a year-on-year increase of 21.27%[40]. - The net profit attributable to shareholders was RMB 1.779 billion, a year-on-year decrease of 5.35%, primarily due to investment losses recognized under the equity method[40]. - Total assets reached RMB 31.928 billion, an increase of 4.83% compared to the end of the previous year[40]. - Net assets attributable to shareholders amounted to RMB 29.634 billion, reflecting a 2.83% increase from the previous year[40]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 0.30 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[1]. - The company aims to share its development achievements with investors through stable cash dividends and stock repurchases, reinforcing investor confidence[38]. - The total distributable profit for 2023 was RMB 3,814,996,859.17, with cash dividends accounting for 100% of the profit distribution[156]. Market and Product Development - The company is focusing on new product development and technological advancements to enhance its product offerings[2]. - Market expansion strategies are being implemented to increase the company's footprint in both domestic and international markets[2]. - The blood products market demand significantly increased in 2023, with notable growth in human albumin and intravenous immunoglobulin markets[17]. - The company anticipates a new development cycle in the blood products industry due to rising market demand and enhanced public awareness[17]. - The company has a comprehensive product range, including albumin, immunoglobulin, and coagulation factor products, and is one of the few in China capable of extracting six components from plasma[24]. - The company is actively engaged in R&D for hemophilia treatment, with a recent innovative study published in the journal Blood, highlighting advancements in targeted therapies[25]. - The company plans to enhance its product line and competitiveness through ongoing research and development initiatives[59]. Operational Efficiency and Cost Management - The company reported a significant increase in investment cash inflow, totaling ¥1,464,766,164.09, a 168.07% increase compared to the previous year[62]. - The company has implemented digital management systems, including LIMS and plasma information management systems, to enhance quality management and ensure product safety[36]. - The company has successfully restructured its marketing system, enhancing market share in key academic regions, particularly in hospital channels, contributing to long-term business health[26]. - The company has implemented a comprehensive production quality management system, ensuring strict inspection and evaluation of materials and products before use[31]. - The company has strengthened its marketing team and optimized its promotional strategies, resulting in an increase in market share for its main products[35]. - The company has implemented cost-cutting measures, resulting in a 5% reduction in operational expenses, saving approximately $50 million annually[125]. Strategic Partnerships and Acquisitions - The company signed a transfer agreement in August 2023 to acquire rights related to Single Molecule Counting technology for $202 million, equivalent to approximately ¥1,425,271,600.00[12]. - The company has established a strategic partnership with 基立福, focusing on quality management and innovative collaboration in the blood products sector[24]. - The company has successfully executed a series of acquisitions, significantly enhancing its comprehensive capabilities and profitability in the blood product industry[26]. - The company acquired a 95% stake in Guangxi Laisi for RMB 481,519,331.35, with the investment completed during the reporting period[71]. - GDS acquired 95% of Guangxi Laishi Biological Pharmaceutical Co., Ltd., enhancing its strategic layout in Guangxi province, a key area for plasma collection[104]. Compliance and Governance - The company emphasizes the importance of accurate financial reporting and compliance with regulatory standards[1]. - The company has strengthened information disclosure and investor relations management to protect investors' rights[113]. - The company’s governance structure complies with the requirements of the Company Law and other regulations, with no significant discrepancies noted[113]. - The company has not reported any significant internal control deficiencies or important deficiencies during the period[160]. - The internal control evaluation report indicates that the company maintained effective financial controls as of December 31, 2023[165]. Environmental Responsibility - The company is subject to multiple environmental protection laws and regulations, including the Environmental Protection Law and the Water Pollution Prevention Law[167]. - The company has implemented measures to comply with the Air Pollution Prevention Law and the Solid Waste Pollution Prevention Law[168]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[167]. - The company is committed to enhancing its environmental risk prevention capabilities in line with national policies[168]. - The company follows the guidelines for volatile organic compounds (VOCs) control as outlined in the relevant environmental standards[169]. Leadership and Management Changes - The company has undergone a leadership transition with the appointment of new executives and board members, indicating a strategic shift[119]. - Jun Xu was appointed as the new CEO on October 19, 2022, and later became the chairman on April 26, 2023[119]. - The previous CEO, Chen Jie, resigned on October 1, 2022, and the chairman position was vacated on April 25, 2023, both due to personal reasons[118]. - The company is focusing on maintaining stability in leadership while pursuing growth opportunities in the market[119]. - The board's restructuring aims to enhance governance and strategic direction moving forward[120].

上海莱士血液制品股份有限公司 简式权益变动报告书 上市公司：上海莱士血液制品股份有限公司 上市地点：深圳证券交易所 股票简称：上海莱士 股票代码：002252 信息披露义务人声明 一、本报告书系信息披露义务人依据《公司法》《证券法》《收购办法》《公开发行证 券的公司信息披露内容与格式准则第 15 号—权益变动报告书》及其他相关法律、法规 及规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》及《收购办法》的规定，本报告书已全面披露了信息披露义务 人在上海莱士拥有权益的股份变动情况。截至本报告书签署之日，除本报告书披露的信 息外，信息披露义务人没有通过任何其他方式增加或减少其在上海莱士中拥有权益的股 份。 信息披露义务人：Grifols, S.A. 住所及通讯地址：Carrer Jesús y María 6, 08022 Barcelona, Spain 权益变动性质：股份减少（协议转让、表决权委托） 签署日期：2023 年 12 月 29 日 上海莱士血液制品股份有限公司 简式权益变动报告书 四、本次权益变动需取得深交所关于本次权益变动项下股份转让的合规性审查确认 与 ...

上海莱士血液制品股份有限公司 关于深圳证券交易所问询函回复的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"上海莱士"或"公司"）于 2023 年 11 月 15 日收到深圳证券交易所（"深交所"）出具的《关于对上海莱士血液制品股份有限 公司的问询函》（公司部问询函〔2023〕第 227 号）（"问询函"），深交所对公司 相关事项表示关注，公司董事会按照问询函的要求进行了核查，现对该问询函内 容回复并公告如下： 一、公告显示，广西冠峰为广西自治区唯一的血液制品生产企业，核心资 产包括一家位于南宁市的具有人血白蛋白、静脉注射用人免疫球蛋白、人免疫 球蛋白三个产品品种、年产能为 200 吨血浆的血液制品生产企业，以及两个已 经建成的单采血浆站。2022 年度和 2023 年 1-8 月，广西冠峰无营业收入，实现 归母净利润分别为-1,699.54 万元和-1,032.96 万元。 （一）请你公司补充披露广西冠峰近三年及一期的主要财务数据，并结合 广西冠峰具体业务、经营模式、核心竞争力、业务成长性、主要客户及订单、 主要财务数据 ...

问询回复函 中立资产评估（北京）有限公司接受上海莱士血液制品股份有限 公司的委托，就上海莱士血液制品股份有限公司拟收购广西冠峰生物 制品有限公司 95%股权之经济行为，对所涉及的广西冠峰生物制品有 限公司股东全部权益在评估基准日的投资价值进行了评估。 现对以下问题进行回复： 二、资产评估报告显示，以 2023 年 8 月 31 日为评估基准日，广西冠峰账 面净资产为 8,432.05 万元，评估值为 50,600.00 万元，评估增值 42,167.95 万元， 增值率 500.09%。请补充披露广西冠峰资产的具体评估过程，包括估值的测算 方法与测算过程、评估假设的合理性、主要参数的选取及其确定依据，并结合 市场可比交易说明资产评估的公允性。请评估机构核查上述事项并发表明确意 见。 答复： 评估机构回复： （一）评估方法 1、评估方法选择 本次评估目的是上海莱士血液制品股份有限公司拟收购广西冠峰生物制品 有限公司 95%股权。 根据本次评估目的，鉴于生物制品企业资产价值的特点，其许多因素对未来 收益有很大影响的资产，未在账面计量，采用资产基础法无法估算其价值。且考 虑上海莱士与广西冠峰业务协同、经营协同、财务 ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-076 上海莱士血液制品股份有限公司 关于减少公司注册资本暨修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据公司回购股份实施结果，公司注销存放于回购专用证券账户的 95,307,149股股份，并相应减少公司注册资本。经中国证券登记结算有限责任公 司深圳分公司确认，公司本次回购股份注销事宜已于2023年11月22日办理完成。 鉴于前述情况，公司拟对《公司章程》中涉及注册资本、股份总数条款进行相应 修改如下： | | 修订前 | 修订后 | | --- | --- | --- | | 第六条 | 公司注册资本为人民币6,740,787,907 | 公司注册资本为人民币6,645,480,758 | | | 元。 | 元。 | | 第十九条 | 股份总数为 6,740,787,907 股，每股面值 | 股份总数为 6,645,480,758 股，每股面值 | | | 一元人民币，公司的股本结构为：普通股 | 一元人民币，公司的股本结构为：普通股 | | | 股。 6,740, ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-077 上海莱士血液制品股份有限公司 关于召开2023年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于2023年11月23日召开第五届董 事会第二十九次（临时）会议，审议通过了《关于召集2023年第三次临时股东大 会的议案》，会议定于2023年12月11日（星期一）14:00召开公司2023年第三次临 时股东大会，现将本次股东大会的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：上海莱士 2023 年第三次临时股东大会； 2、股东大会的召集人：公司第五届董事会； 3、会议召开的合法、合规性：公司董事会召集本次股东大会会议符合有关 法律、行政法规、部门规章、规范性文件以及《公司章程》等有关规定； 4、会议召开的日期、时间： 现场会议召开时间为：2023 年 12 月 11 日（星期一）14:00； 网络投票时间为：2023 年 12 月 11 日（星期一）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-075 上海莱士血液制品股份有限公司 关于第五届董事会第二十九次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"上海莱士"、"公司"）第五届董事会第二 十九次（临时）会议于 2023 年 11 月 17 日以电话和邮件方式发出会议通知，并 于 2023 年 11 月 23 日下午 3 点以通讯方式召开。 3、审议通过了《关于召集2023年第三次临时股东大会的议案》 本次会议应出席董事 9 名，实际出席会议董事 9 名。会议由公司董事长、总 经理 Jun Xu（徐俊）先生主持。会议的召集、召开与表决程序符合《公司法》和 《公司章程》等有关规定。会议在保证所有董事充分发表意见的前提下，全体与 会董事经投票表决，一致作出如下决议： 1、审议通过了《关于减少公司注册资本的议案》 根据公司 2023 年第一次临时股东大会审议通过的股份回购方案，本次回购 用于依法注销减少注册资本或实施股权激励/员工持股计划，其中用于实施股权 激励/员工持股计划的股份占本次 ...